Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
- Conditions
- Unresectable MelanomaMetastatic Melanoma
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04625205
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Brussel, Belgium
🇳🇱Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03597282
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of Colorado Denver, Denver, Colorado, United States
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell LungLung CancerNonsquamous Nonsmall Cell Neoplasm of Lung
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03380871
- Locations
- 🇺🇸
University of California - Los Angeles, Santa Monica, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
- Conditions
- Urinary Bladder CancerBladder TumorsMelanomaTransitional Cell Carcinoma of the BladderMalignant MelanomaCarcinoma, Non-Small-Cell LungSkin CancerLung Cancer
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02897765
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States